Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.35 |
| ▸ | FABP7 | O15540 | 1/20 | 0.35 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2501975 | 1.00 | KMT2A (0.36) | KMT2AFABP5FABP7SOAT2SOAT1 | |
| SCHEMBL307644 | 0.91 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2TLR2 | |
| SCHEMBL29883728 | 0.91 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2TLR2 | |
| SCHEMBL2499585 | 0.85 | TLR2 (0.36) | KMT2AFABP5FABP7TLR2 | |
| SCHEMBL2499582 | 0.85 | TLR2 (0.36) | KMT2AFABP5FABP7TLR2 | |
| SCHEMBL28416919 | 0.84 | KMT2A (0.40) | KMT2AFABP5FABP7EPHX2TLR2 | |
| SCHEMBL6285017 | 0.82 | KMT2A (0.40) | KMT2AFABP5FABP7EPHX2TLR2 | |
| SCHEMBL15020545 | 0.78 | TLR2 (0.39) | KMT2AFABP5FABP7SOAT2SOAT1 | |
| SCHEMBL4951862 | 0.78 | KMT2A (0.42) | KMT2ASOAT2SOAT1EPHX2TLR2 | |
| SCHEMBL725370 | 0.78 | TLR2 (0.39) | KMT2AFABP5FABP7SOAT2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030445-B2 | Glycopeptide derivative | THERAVANCE, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-7723470-B2 | Glycopeptide derivatives and pharmaceutical compositions containing the same | THERAVANCE, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090215982-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CUMBERLAND PHARMACEUTICALS INC. | 2009-08-27 | — | — | US | disclosed |
| US-20080103292-A1 | Glycopeptide derivatives and pharmaceutical compositions containing the same | CUMBERLAND PHARMACEUTICALS INC. | 2008-05-01 | — | — | US | disclosed |
| US-7351791-B2 | Intermediate for preparing glycopeptide derivatives | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060241024-A1 | Intermediate for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2006-10-26 | — | — | US | disclosed |
| US-7101964-B2 | Intermediate for preparing glycopeptide derivatives | THERAVANCE, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-6962970-B2 | Glycopeptide derivatives and pharmaceutical compositions containing the same | THERAVANCE, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050239690-A1 | Intermediate for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2005-10-27 | — | — | US | disclosed |
| US-6949681-B2 | Intermediate for preparing glycopeptide derivatives | THERAVANCE, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040204346-A1 | Intermediate for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1140993-B1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | THERAVANCE INC (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030060598-A1 | Glycopeptide derivatives and pharmaceutical compositions containing the same | CUMBERLAND PHARMACEUTICALS INC. | 2003-03-27 | — | — | US | disclosed |
| US-20030008812-A1 | Glycopeptide derivatives | THERAVANCE, INC. | 2003-01-09 | — | — | US | disclosed |
| US-6455669-B1 | GLYCOPROTEIN FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS | THERAVANCE, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6444786-B1 | BACTERICIDES | ADVANCED MEDICINE, INC. | 2002-09-03 | — | — | US | disclosed |
| US-6392012-B1 | COMPOUND FOR USE IN TREATMENT AND PREVENTION OF BACTERIAL INFECTION | ADVANCED MEDICINE, INC. | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103292-A1 | Glycopeptide derivatives and pharmaceutical compositions containing the same | GYPA, RDX, VIP | KMT2A 4618/4885FABP5 3103/4885FABP7 4367/4885 |
| US-20050239690-A1 | Intermediate for preparing glycopeptide derivatives | GYPA, MGAT3, RDX | KMT2A 4596/4885FABP5 3434/4885FABP7 4643/4885 |
| US-20090215982-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | GYPA, RDX, VIP | KMT2A 4618/4885FABP5 3103/4885FABP7 4367/4885 |
| US-20040204346-A1 | Intermediate for preparing glycopeptide derivatives | NGLY1, FUT6, ST3GAL3 | KMT2A 4082/4885FABP5 919/4885FABP7 2178/4885 |
| US-20030008812-A1 | Glycopeptide derivatives | MGAT3, GYPA, GIPR | KMT2A 4608/4885FABP5 2718/4885FABP7 3062/4885 |
| US-20060241024-A1 | Intermediate for preparing glycopeptide derivatives | B3GAT3, ST3GAL3, OGT | KMT2A 4309/4885FABP5 760/4885FABP7 2448/4885 |
| US-20030060598-A1 | Glycopeptide derivatives and pharmaceutical compositions containing the same | GYPA, RDX, MGAT3 | KMT2A 4792/4885FABP5 3054/4885FABP7 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.